Ingredients for functional drinks in neurodegenerative diseases: A review

Natural Product Communications

Volumn 4, Issue 5, 2009, Pages 719-740

  Zafrilla, Pilar ^a   Morillas, Juana M ^a   Rubio Perez, José M ^a   Cantos Villar, Emma ^b  

^a CATHOLIC UNIVERSITY OF MURCIA   (Spain)

^b IFAPA CENTRO EL TORUÑO   (Spain)

Author keywords

Antioxidant activity; Functional ingredients; Neurodegenerative diseases; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTHOCYANIN; ASCORBIC ACID; BETA CAROTENE; CATECHIN; CURCUMIN; FLAVANOL DERIVATIVE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; GLUTATHIONE; HESPERIDIN; ISOFLAVONE; LEUKOTRIENE; NARINGENIN; OMEGA 3 FATTY ACID; PLACEBO; PROSTAGLANDIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SCAVENGER; SELENIUM; SELENOCYSTEINE; SELENOPROTEIN; THIOCTIC ACID; THROMBOXANE DERIVATIVE; UBIQUINONE; UNINDEXED DRUG; VITAMIN B GROUP; ZINC;

AEROBIC METABOLISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BEVERAGE; BLOOD BRAIN BARRIER; CELL VIABILITY; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; FRUIT; FRUIT JUICE; GLYCEMIC CONTROL; HEAVY METAL POISONING; HUMAN; IN VITRO STUDY; INFECTION; LYSOSOME; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARKINSON DISEASE; POLYNEUROPATHY; REVIEW; RHIZOME; RISK ASSESSMENT; RISK REDUCTION; TEA; TREATMENT DURATION; VEGETABLE; VITAMIN SUPPLEMENTATION; WINE;

ANIMALIA;

EID: 77953231522     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x0900400508     Document Type: Review

References (115)

1. Casetta I, Govoni V, Granieri E. (2005) Oxidative stress, antioxidants and neurodegenerative diseases: Oxidative balance: Experimental and clinical perspectives. Current Pharmaceutical Design, 16, 2033-2052.
2. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. (2006) Involvement of oxidative stress in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 65, 631-641. (Pubitemid 44297254)
3. Emerit J, Edeas M, Bricaire F. (2004) Neurodegenerative diseases and oxidative stress. Biomedicine & Pharmacotherapy, 58, 39-46.
4. Kedar NP. (2003) Can We prevent Parkinson's and Alzheimer's disease? Journal of Postgraduate in Medicine, 49, 236-245.
5. Packer L, Weber SU, Rimbach G. (2001) Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling, The Journal of Nutrition, 131, 369S-73S.
6. Traber MG, Atkinson J. (2007) Vitamin E, antioxidant and nothing more. Free Radical Biological Medicine, 43, 4-15.
7. U.S. Department of Agriculture, Agricultural Research Service. (2004) USDA National Nutrient Database for Standard Reference, Release 16-1. Nutrient Data Laboratory Home.
8. Meister A (1994) Glutathione-ascorbic acid antioxidant system in animals. Journal of Biological Chemistry, 269, 9397-9400.
9. Linder MC. (1991) Food quality and its determinants from field to table growing food, its storage and preparation, Chapter 10. In: M Linder (ed) Nutritional Biochemistry and Metabolism with Clinical Applications, Elsevier, New York, London; 239-254.
10. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal Medicine, 352, 2379-2388. (Pubitemid 40958434)
11. Vile GF, Winterbourn CC. (1988) Inhibition of adriamycin-promoted microsomal lipid peroxidation by beta-carotene, alpha-tocopherol and retinol at high and low oxygen partial pressures. FEBS Letters, 238, 353-356.
12. Goodman Y, Mattson MP. (1994) Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Experimental Neurology, 128, 1-12. (Pubitemid 24278360)
13. Arlt S, Müller-Thomsen T, Beisiegel U. (2002) Use of vitamin C and E in the treatment of Alzheimer's disease. Drug Development Research, 56, 452-457. (Pubitemid 35168322)
14. Kontush K, Schekatolina S. (2004) Vitamin E in neurodegenerative disorders: Alzheimer's disease. Annals of the New York Academy of Sciences, 1031, 249-262. (Pubitemid 40361760)
15. Fukui K, Omoi NO, Hayasaka T, Shinnkai T, Suzuki S, Abe K, Urano S. (2002) Cognitive impairment of rats caused by oxidative stress and aging, and its prevention by vitamin E. Annals of the New York Academy of Sciences, 95, 275-284. (Pubitemid 34457568)
16. Pillai SR, Traber MG, Steiss JE, Kayden HJ, Cox NR. (1993) Alpha-tocopherol concentrations of the nervous system and selected tissues of adult dogs fed three levels of vitamin E. Lipids, 28, 1101-1105.
17. Martin A, Cuervo A, Dice J, Joseph J. (2000) Effect of vitamin C on intracellular protein turnover in human glial cells. Presented at Society for Neuroscience Annual Meeting: 1830a.
18. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal Medicine, 336, 1216-1222.
19. Grundman M. (2000) Vitamin E and Alzheimer disease: the basis for additional clinical trials1,2,3. American Journal of Clinical Nutrition, 71, 630S-636S.
20. Isaac Mgekn, Quinn R, Tabet N. (2008) Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews, Issue 4. John Wiley & Sons, Ltd Chichester, UK DOI:10.1002/14651858. CD002854
21. O'hare E, McDiad D, Wilson R, Kennedy F, Kim E. (2000) Chronic alpha-tocopherol administrtion protects against behavioral impairment induced following intra-hipocampal Aß injection. Presented at Society for Neuroscience Annual Meeting: 1788a.
22. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR. (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology, 54, 1265-1272. (Pubitemid 30174045)
23. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM. (2002) Dietary intake of antioxidants and risk of Alzheimer disease. Journal of the American Medical Association, 287, 3223-3229. (Pubitemid 34686103)
24. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, Evans DA. (1998) Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Disease & Associated Disorder, 12, 121-126.
25. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA. (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracialcommunity study. Journal of the American Medical Association, 287, 3230-3237. (Pubitemid 34686104)
26. Pham DQ, Plakogiannis R. (2005) Vitamin E Supplementation in cardiovascular disease and cancer prevention: Part 1 The Annals of Pharmacotherapy, 39, 1870-1888.
27. Boothby LA, Doering PL. (2004) Vitamin C and vitamin E for Alzheimer's disease, The Annals of Pharmacotherapy, 39, 2073-2080.
28. Fillenbaum GG, Maragatha NK, Hanlon, JT, Artz MB, Pieper CF, Schmader KE, Dysken MW, MD, Gray SL. (2005) Dementia and Alzheimer's Disease in community-dwelling elders taking vitamin C and/or vitamin E. The Annals of Pharmacotherapy, 39, 2009-2014.
29. Etminan M, Gill SS, Samii A. (2005) Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurology, 4, 362-365. (Pubitemid 40720032)
30. (a) Ramassamy C. (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. European Journal of Pharmacology, 545, 51-64;
31. (b) Kyle J, Duthie G. (2006) Nutritional relevance of flavonoids in disease prevention. Natural Product Communications, 1, 1049-1060.
32. Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C. (2008) Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. Journal of Agricultural and Food Chemistry, 56, 4855-4873. (Pubitemid 352039080)
33. Kroon PA, Clifford MN, Crozier A. (2004) How should we assess the effects of exposure to dietary polyphenols in vitro? American Journal Clinical Nutrition, 80, 15-21.
34. Rice-Evans CA, Miller NJ. (1996) Paganga G. Structure- antioxidant actiivity relationships of flavonoids and phenolics acids. Free Radical Biology and Medicine, 20, 993-956.
35. Scalbert A, Williamson G. (2000) Dietary intake and bioavailability of polyphenols. Journal Nutrition, 130, 2073S-85S.
36. Manach C, Williamson G, Scalbert A, Rémésy C. (2005) Bioavailability and bioefficacy of polyphenols in humans.I. Review of 97 bioavailability studies. American Journal Clinical Nutrition, 81S, 230-242.
37. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. (2004) Polyphenols: food sources and 97 bioavailability studies. American Journal Clinical Nutrition, 79, 727-747.
38. Moon JH, Nakata R, Oshima S, Inakuma T, Terao J. (2000) Accumulation of quercetin conjugates in blood plasma after the short-term ingestion of onion by women. American Journal of Physiology-Regulatory, Integrative, and Comparative Physiology, 279, 461R-467R.
39. Zhang Y, Song TT, Cunnick JE, Murphy PA, Hendrich S. (1999) Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. Journal Nutrition, 129, 399-405.
40. Spencer JP, Schroeter H, Crossthwaithe AJ, Kuhnle G, Williams RJ, Rice-Evans C. (2001) Contrasting influences of glucuronidation and o-methylation of epicathechin on hydrogen peroxide-induced cell death in neurons and fibroblasts. Free Radical Biology and Medicine, 31, 1139-1146.
41. Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H. (1998) Wide distribution of (-) epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis, 19, 1771-1776.
42. Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice-Evans C. (2003) Interaction between flavonoids and the blood - brain barrier: in vitro studies. Journal of Neurochemistry, 85, 180-192.
43. Letenneur L, Proust-Lima C, Le Gouge A, Dartigues J, Barberger-Gateau P. (2007) Flavonoid intake an cognitive decline over a 10-year period. American Journal of Epidemiology, 165, 1364-1371.
44. Bastianetto S, Yao Z, Papadopoulos V, Quirion R. (2006) Neuro protective effects of green and black teas and their catechin gallate esters against β-amyloid induced toxicity. European Journal of Neuroscience, 23, 55-64.
45. Lau FC, Shukitt-Hale B, Joseph JA. (2005) The beneficial effects of fruit polyphenols on brain aging. Neurobiology of Aging, 26(S1), 128-132.
46. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM. (2008) Moderate consumption of Cabernet Sauvignon attenuates Aß neuropathology in a mouse model of Alzheimer's disease. Journal of Neurosciencce, 28, 6388-6392.
47. Wang Y, Chang CF, Chou J, Chen HL, Deng X, Harvey BK, Cadet JL, Bickford PC. (2005) Dietary supplementation with blueberries, spinach or spirulina reduces ischemic brain damage. Experimental Neurology, 193, 75-84. (Pubitemid 40463269)
48. (a) Miquel J, Bernd A, Sempere JM, Díaz-Alperi J, Ramírez A. (2002) The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Archives of Gerontology and Geriatrics, 34, 37-46;
49. (b) Ali BH, Marrif H, Noureldayem SA, Bakheit AO, Blunden G. (2006) Some biological properties of curcumin: a review. Natural Product Communications, 1, 509-521.
50. Ammon HP, Safayhi H, Mack T, Sabieraj J. (1993) Mechanism of antiinflammatory actions of curcumine and boswellic acids. Journal of Ethnopharmacology, 38, 113-119. (Pubitemid 23136055)
51. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. (2003) Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. Journal of Neurochemistry, 87, 172-181. (Pubitemid 37210651)
52. Anekonda TS. (2006) Resveratrol-a boon for treating Alzheimer's disease? Brain research reviews, 52, 316-326.
53. Sharma M, Gupta Y.K. (2002) Chronic treatment with trans-resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sciences, 71, 2489-2498. (Pubitemid 35251893)
54. Blanchet J, Longpré F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG. (2008) Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 1243-1250
55. YJ, Sur, Surh YJ. (2003) Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radical Biology and Medicine, 34, 1100-1110. (Pubitemid 36398570)
56. Carluccio MA, Siculella L, Ancora MA, Massaro M, Scoditti E, Storelli C, M. Carluccio, , A. Distante, De Caterina R (2003) Olive Oil and Red Wine Antioxidant Polyphenols Inhibit Endothelial Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 622-629.
57. Savaskan E, Olivieri G, Meier F, Seifritz E, Wirz-Justice A, Müller-Spahn F. (2003) Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology, 49, 380-383 (Pubitemid 37465118)
58. Diplock AT. (1992) Selenium, antioxidant nutritions, and human diseases. Biological Trace Element Research, 33, 155-156.
59. Chen J, Marla B. (2003) Selenium and selenoproteins in the brain and brain diseases. Journal of Neurochemistry, 86, 1-12.
60. Rink L, Gabriel P. (2000) Zinc and the immune system. Proceedings of the Nutrition Society, 59, 541-552.
61. Sandstrom B. (1997) Bioavailability of zinc. Proceedings of the Nutrition Society, 51, S17-S19.
62. Wise A. (1995) Phytate and zinc bioavailability. International Journal of Food Sciences and Nutrition, 46, 53-63.
63. Towner RA, Appleby C, Levy M, Bray TM. (2004) Zinc deficiency and oxidative stress in brain: Magnetic resonance investigations in weanling rats. The Journal of Trace Elements in Experimental Medicine, 17, 161-174. (Pubitemid 38982210)
64. Shults CW. (2003) Coenzyme Q10 in neurodegenerative diseases. Current Medicinal Chemistry, 10, 1917-1921.
65. Whelan J, Rust C. (2006) Innovative dietary sources of n-3 fatty acids. Annual Review of Nutrition, 26, 75-103.
66. Satoh N, Shumatsu A, Kotani K, Sakane N, Yamada K, Suganami T, Kuzuya H, Ogawa Y. (2007) Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care, 30, 144-146. (Pubitemid 46061295)
67. Griel AE, Kris-Etherton PM, Hilpert KF, Zhao G, West SG, Corwin RL. (2007) An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans. Nutrition Journal, 6, 2-10.
68. Severus WE, Littman AB, Stoll AL. (2001) Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harvard Review of Psychiatry, 9, 280-293.
69. Mantzioris E, Cleland LG, Gibson RA, Neumann MA, Demasi M, James MJ. (2000) Biochemical effects of a diet containing foods enriched with n-3 fatty acids. American Journal of Clinical Nutrition, 72, 42-48.
70. Beltz BS, Tlusty MF, Benton JL, Sandeman DC. (2007) Omega-3 fatty acids upregulate adult neurogenesis. Neuroscience Letters, 415, 154-158. (Pubitemid 46394591)
71. Kris-Etherton, PM, Harris WS, Appel, LJ. (2003) Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 151-152.
72. Kris-Etherton PM, Harris WS, Appel LJ. (2003) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, e20-e30.
73. Harris WS, Assaad B, Poston WC. (2006) Tissue omega-6/omega-3 fatty acid ratio and risk for coronary artery disease. American Journal of Cardiology, 98, 19i-26i.
74. Calon F, Cole G. (2007) Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins, Leucotrienes and essential fatty acids Prostaglandins, 77, 287-293.
75. Julien C, Tremblay C, Phivilay A, Berthiaume L, Emond V, Julien P, Calon F. (2008) High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiology of Aging, in press.
76. Bousquet M, Saint-Pierre M, Julien C, Salem N, Cicchetti JF, Calon F. (2008) Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. Journal of the Federation of American Societies for Experimental Biology, 22, 1213-1225.
77. Yehuda S, Rabinovtz S, Carasso RL, Mostofsky DI. (1996) Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life. International Journal of Neuroscience, 87, 141-149.
78. Terano T, Fujishiro S, Ban T, Yamamoto, K, Tanaka T, Noguchi, Y, Tamura, Y, Yazawa K, Hirayama T. (1999) Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids, 34, S345-S346.
79. Peers RJ. (1990) Alzheimer's disease and omega-3 fatty acids: hypothesis. Medical Journal, 153, 563-564.
80. Sears B. (2002) The Omega Rx Zone. Harper-Collins, New York.
81. Reed LJ. (2001) A trail of research from lipoic acid to alpha-keto acid dehydrogenase complexes. Journal of Biological Chemistry, 276, 38329-38336.
82. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. (2004) Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Current Medicinal Chemistry, 11, 1135-1146.
83. Kramer K, Packer L. (2001) R-alpha-lipoic acid. In: Kramer K, Hoppe P, Packer L, eds. Nutraceuticals in health and disease prevention. New York: Marcel Dekker, Inc.129-164.
84. Jones W, Li X, Qu ZC, Perriott L, Whitesell RR, May JM. (2002) Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radical Biology and Medicine, 33, 83-93.
85. May JM, Qu ZC, Mendiratta S. (1998) Protection and recycling of alpha-tocopherol in human erythrocytes by intracellular ascorbic acid. Archives of Biochemistry and Biophysics, 349, 281-289.
86. Kozlov AV, Gille L, Staniek K, Nohl H. (1999) Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Archives of Biochemistry and Biophysics, 63, 148-154.
87. Upston JM, Terentis AC, Stocker R. (1999) Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. Journal of the Federation of American Societies for Experimental Biology, 13, 977-994.
88. Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, Bartholomew JC, Ames BN. (2002) Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 99, 1870-1875.
89. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN. (2002) Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proceedings of the National Academy of Sciences of the United States of America, 99, 2356-2361.
90. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE. (2003) The antioxidants alphalipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. Journal of Neurochemistry, 84, 1173-1183. (Pubitemid 36330669)
91. Milgram NW, Head E, Zicker SC, Ikeda-Douglas CJ, Murphey H, Muggenburg B, Siwak C, Tapp D, Cotman CW. (2005) Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiology Aging, 26, 77-90. (Pubitemid 39600593)
92. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. The New England Journal of Medicine, 346, 476-483. (Pubitemid 34441738)
93. Whyte EM, Mulsant BH, Butters MA, Qayyum M, Towers A, Sweet, RA, Klunk W, Wisniewski S, DeKosky ST. (2002) Cognitive and behavioral correlates of low vitamin B12 levels in elderly patients with progressive dementia. American Journal of Geriatry and Psychiatry, 10, 321-327. (Pubitemid 34517687)
94. Johnson, MA, Hawthorne, NA, Brackett, WR, Fischer, JG, Gunter, EW, Allen, RH, Stabler, SP. (2003) Hyperhomocysteinemia and vitamin B-12 deficiency in elderly using Title IIIc nutrition services. American Journal of Clinical Nutrition, 77, 211-220.
95. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. (2001) Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology, 56, 1188-1194. (Pubitemid 32405713)
96. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Archives of Neurology, 55, 1449-1455. (Pubitemid 28525506)
97. Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR. (2000) Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. American Journal of Clinical Nutrition, 71, 993-998.
98. Miller J W. (2002) Vitamin B12 deficiency, tumor necrosis factor-alpha, and epidermal growth factor: a novel function for vitamin B12? Nutrition Reviews, 60, 142-144.
99. Weir DG, Molloy A. (2000) Microvascular disease and dementia in the elderly: are they related to hyperhomocysteinemia. American Journal of Clinical Nutrition, 71, 859-860. (Pubitemid 30176565)
100. Abyad A. (2002) Prevalence of Vitamin B12 deficiency among demented patients and cognitive recovery with cobalamin replacement, Journal of Nutrition Health Aging, 6, 254-260.
101. Eastley R, Wilcock GK, Bucks RS. (2000) Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. International Journal of Geriatric and Psychiatry, 15, 226-233. (Pubitemid 30179173)
102. Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. (1998) Effective treatment of cobalamin deficiency with oral cobalamin. Blood, 92, 1191-1198.
103. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N. (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nature Medicine, 10, 148-154. (Pubitemid 38524884)
104. Davies J E, Sarkar S, Rubinsztein DC. (2006) Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Human Molecular Genetics, 15, 23-31.
105. Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. (2005) Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiology Disease, 20, 74-81.
106. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy, Tan D. (2006) Caffeine protects Alzheimer's miceagainst cognitive impairment and reduces brain beta-amyloid production. Neuroscience, 142, 941-952.
107. Ritchie K, Carrière I, de Mendona A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin, ML. (2007) The neuroprotective effects of caffeine. A prospective population study (the Three City Study), Neurology, 69, 536-545.
108. Chen X, Gawryluk JW, Wagener JF, Ghribi O, Geiger JD. (2008) Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. Journal of Neuroinflammation, 5, 1-14.
109. Wu JN, Ho SC, Zhou C, Ling WH, Chen WQ, Wang CL, Chen YM. (2008) Coffee consumption and risk of coronary heart diseases: A meta-analysis of 21 prospective cohort studies. International Journal of Cardiology, Aug 14.
110. Solomon PR, Adams F, Silver, A, Zimmer J, DeVeaux R. (2002) Ginkgo for memory enhancement: a randomized controlled trial, Journal of the American Medical Association, 288, 835-840.
111. Fotuhi M. (2003) The Memory Cure. New York, McGraw Hill.
112. Birks J, Grimley EV, Van Dongen M. (2002) Ginkgo biloba for cognitive impairment and dementia. Cochrane.Database. System Review. No. 4, CD003120.
113. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H., Butko P. (2002) Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proceedings of the National Academy of Sciences of the United States of America, 99, 12197-12202.
114. Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset PJ, Albarede JL, Vellas B, Grandjean H. (2003) Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 58, 372-377.
115. Lee ST, Chu K, Sim JY, Heo JH, Kim M. (2008) Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Disease and Associated Disorders, 22, 222-226.